Dec 09, 2020
Taiho Oncology, Inc. Announces Establishment of European Headquarters
Nov 23, 2020
National Comprehensive Cancer Network® Adds INQOVI® (decitabine and cedazuridine) Tablets to its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes
Oct 23, 2020
Taiho Oncology Launches World of Hope Campaign to Support MDS World Awareness Day
Jun 04, 2020
Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020
Jan 25, 2020
Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Futibatinib (TAS-120) at ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI)
Nov 01, 2019
Taiho Oncology Joins Efforts to Improve Awareness of Gastric Cancer with Support of Leading Advocacy Groups
Jun 07, 2019
Taiho Oncology Announces Agreement with Otsuka to Commercialize Astex Pharmaceuticals' Drug Candidates
Jun 03, 2019
Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Data at the 2019 ASCO Annual Meeting
Mar 01, 2019
Taiho Oncology Announces Support of Colorectal Cancer Awareness Month Through Research and Awareness Initiatives
Feb 25, 2019
FDA Approves Taiho Oncology's LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Jan 17, 2019
Taiho Oncology and Servier Present Data on LONSURF® (trifluridine/tipiracil) at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI)
Oct 21, 2018
Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology
Sep 28, 2018
Taiho Oncology Presents Real-World Adherence Data for LONSURF® (trifluridine and tipiracil) in Metastatic Colorectal Cancer at ASCO Quality of Care Symposium
Jun 21, 2018
Taiho Oncology and Servier Present Data on LONSURF® (trifluridine and tipiracil) at ESMO 20th World Congress on Gastrointestinal Cancer 2018
Jun 07, 2018
Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF® (trifluridine and tipiracil)
May 09, 2018
Taiho Oncology Announces Positive Topline Results from Pivotal Phase 3 Trial of LONSURF® (trifluridine/tipiracil) in Metastatic Gastric Cancer
Apr 13, 2018
Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compounds at the 109th Annual Meeting of the American Association for Cancer Research
Mar 08, 2018
Taiho Oncology Announces Support of Awareness and Research Initiatives to Mark Colorectal Cancer Awareness Month
Jan 20, 2018
Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Metastatic Colorectal Cancer (mCRC) Data at ASCO 2018 Gastrointestinal Cancers Symposium
Jan 12, 2018
Taiho Oncology Announces Multiple LONSURF® (trifluridine and tipiracil) Presentations at ASCO 2018 Gastrointestinal Cancers Symposium